Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

0.6150
+0.03496.02%
Post-market: 0.69480.0798+12.98%19:59 EST
Volume:11.64M
Turnover:7.25M
Market Cap:79.44M
PE:-2.62
High:0.6358
Open:0.6109
Low:0.5900
Close:0.5801
52wk High:1.29
52wk Low:0.5510
Shares:129.17M
Float Shares:129.10M
Volume Ratio:10.76
T/O Rate:9.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2348
EPS(LYR):-0.2026
ROE:-48.89%
ROA:-29.87%
PB:1.60
PE(LYR):-3.03

Loading ...

Stocks to Watch: Atossa Therapeutics, Union Pacific

Dow Jones
·
Yesterday

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Yesterday

FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen

TIPRANKS
·
Jan 16

BRIEF-Atossa Therapeutics Receives FDA "Study May Proceed" Letter For (Z)-Endoxifen

Reuters
·
Jan 06

FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer

Reuters
·
Jan 06

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

THOMSON REUTERS
·
Jan 06

Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction

Reuters
·
Dec 15, 2025

Atossa Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Dec 13, 2025

Why Are Shares Of Atossa Therapeutics Up Today?

Benzinga_recent_news
·
Dec 12, 2025

FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy

Reuters
·
Dec 11, 2025

Atossa Therapeutics Granted U.S. Patent for Enteric Oral (Z)-Endoxifen Formulations and Treatment Methods

Reuters
·
Dec 09, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

THOMSON REUTERS
·
Dec 09, 2025

Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study

Reuters
·
Dec 02, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025

Atossa Therapeutics Q3 net loss widens as operating costs rise

Reuters
·
Nov 12, 2025

Atossa Therapeutics Secures Israeli Patent for (Z)-Endoxifen, Strengthening Global IP Portfolio

Reuters
·
Nov 12, 2025

Atossa Therapeutics Q3 Pretax Profit USD -8.692 Million

THOMSON REUTERS
·
Nov 12, 2025

Atossa Therapeutics Q3 Operating Expenses USD 9.251 Million

THOMSON REUTERS
·
Nov 12, 2025

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025